Since those patients with partial promoter methylation did not show behavioral improvement following AFQ056 treatment, the authors posited that mGluR-5 antagonism might be better suited for FXS patients with full methylation at the Fmr1 promoter. The gene discussed is FMR1; the disease is fragile X syndrome.